The William A. Zoghbi International Research Award aims to provide a springboard for innovative new research in countries outside of the U.S. that hold potential to improve the care and outcomes of ...

The Health Care Innovation Section is open to all members with an interest in developing a vision for the future of cardiology. The Section will collaborate with stakeholders across the American ...

The Cardiovascular Team (CVT) Member Section is a forum for networking and advancing the priorities of the care team within College activities. It offers opportunities for engagement and integration ...

Join ACC's Cardiovascular Imaging Member Section on Tuesday, Aug. 5 at 5:30 p.m. ET for a case-based, multi-modality webinar of the contemporary cardiovascular imaging evaluation of cardiac ...

As part of ACC's ongoing involvement in the American Medical Association (AMA)/Specialty Society Relative Value Scale Update Committee (RUC) process, the College distributes RUC physician work surveys ...

In celebration of Pride Month, please join research leaders from the LGBTQ+ Community as they discuss key research studies showcasing recent findings about care of the LGBTQ+ cardiovascular patient.

The ACC is now accepting applications for the U.S. vice chair of its ACC Latin America conference. The U.S. vice chair works in collaboration with the U.S. and Outside United States (O.U.S.) ...

While cardiovascular disease mortality declined overall from 1999 to 2023, rates increased during the COVID-19 pandemic and recovery across different categories of disease has been uneven, according ...

Overall racial and ethnic differences in Life's Essentials 8 (LE8) scores compared with White adults remained relatively stable over the past decade, although disparities in individual components ...

The microaxial flow pump (mAFP) unloads the heart in STEMI-cardiogenic shock (CS) patients undergoing hemodynamic monitoring with a pulmonary artery catheter (PAC) by reducing native cardiac output ...

A. Initiate a fourth lipid-lowering agent (bempedoic acid) to achieve an LDL-C goal of <70 mg/dL. B. Monitor treatment response over the next 4-12 weeks and adjust therapy to achieve her LDL-C target.

Bempedoic acid is a lipid-lowering medication that works by inhibiting adenosine triphosphate citrate lyase. This inhibition reduces the production of acetyl coenzyme A (acetyl CoA), a precursor of ...